Publications by authors named "I Landego"
Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of lymphoma, yet many patients relapse. Several prognostic markers have been associated with CAR T-cell outcomes, such as tumor burden, response to bridging chemotherapy, and laboratory parameters at the time of lymphodepletion or infusion. The effect of cancer cachexia and weight loss before CAR T cells on toxicity and outcomes is not well understood.
View Article and Find Full Text PDFFollicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies to improve immune-mediated control of FL could significantly benefit this population, particularly as it includes many elderly and comorbid patients.
View Article and Find Full Text PDFArticle Synopsis
- Scientists wanted to see how a treatment called bridging therapy (BT) affects the success of another treatment called CAR T-cell therapy for patients with a type of cancer called large B-cell lymphoma (LBCL).
- They found that many patients who got BT showed a decrease in their cancer's size before the main treatment, which helped them do better overall.
- The study showed that patients who started with high cancer levels could end up doing just as well as those who started with low levels after getting this helpful bridging therapy.
Article Synopsis
- Recent studies highlight concerns about the risk of atrial arrhythmias linked to CAR-T therapy, particularly after CD19-directed treatments.
- A pharmacovigilance study showed that patients receiving CAR-T were nearly four times more likely to experience these arrhythmias compared to other cancer patients, with 10% of 236 patients developing them post-therapy.
- Risk factors identified include a history of atrial arrhythmia and the use of CAR-T with a CD28 costimulatory domain, with arrhythmias often occurring alongside cytokine release syndrome and elevated inflammatory markers.
Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined radiomic features extracted from pre-CAR-T F-fluorodeoxyglucose positron emission tomography/computed tomography ([F]FDG PET/CT) scans (n = 341) of 180 patients (121 male; median age, 66 years). Three conventional (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and 116 novel radiomic features were assessed, along with inflammatory markers, toxicities, and outcomes.
View Article and Find Full Text PDF